Results 31 to 40 of about 93,603 (306)

Metyrapone in treatment-resistant depression [PDF]

Therapeutic Advances in Psychopharmacology, 2012
Depression affects a significant proportion of the population, with 1-year and lifetime prevalence of 3–5% and 10–30% respectively. Full remission is achieved in only a third of patients following treatment with first-line antidepressant. There is a need for novel treatments for treatment-resistant depression (TRD).
Paul David, Sigalas, Himanshu, Garg, Stuart, Watson, Richard Hamish, McAllister-Williams, I Nicol, Ferrier   +4 more
openaire   +2 more sources

Antidepressant discontinuation in treatment resistant depression

Contemporary Clinical Trials Communications, 2019
Treatment-resistant depression (TRD) is a growing problem in psychiatric practice with some 15–20% of depressed patients becoming chronically depressed and perhaps as many as 40% in tertiary settings.
Ziad A. Ali, Sharon Nuss, Rif S. El-Mallakh   +2 more
doaj   +1 more source

Nortriptyline for Treatment-Resistant Depression [PDF]

The Journal of Clinical Psychiatry, 2003
Up to 30% of patients with major depression fail to respond to an antidepressant trial, with most taking a selective serotonin reuptake inhibitor (SSRI) as initial treatment. While the tricyclic antidepressants might be effective for SSRI nonresponders, they have been relegated to third- and fourth-line treatment.
Andrew A, Nierenberg, George I, Papakostas, Timothy, Petersen, Karen E, Kelly, Brian M, Iacoviello, John J, Worthington, Joyce, Tedlow, Jonathan E, Alpert, Maurizio, Fava   +8 more
openaire   +2 more sources

Treatment-Resistant Depression in Poland—Epidemiology and Treatment [PDF]

Journal of Clinical Medicine, 2022
(1) Background: Major depressive disorder (MDD) is one of the most prevalent psychiatric disorders worldwide. Although several antidepressant drugs have been developed, up to 30% of patients fail to achieve remission, and acute remission rates decrease with the number of treatment steps required.
Piotr Gałecki, Jerzy Samochowiec, Magdalena Mikułowska, Agata Szulc   +3 more
openaire   +2 more sources

Treatment-resistant depression in adolescents: is the addition of cognitive behavioral therapy of benefit? [PDF]

, 2011
Sarah E Hetrick1, Georgina R Cox1, Sally N Merry21Orygen Youth Health Research Centre, Centre for Youth Mental Health, Melbourne, Parkville, Victoria, Australia; 2Werry Centre for Child and Adolescent Mental Health, Department of Psychological Medicine ...
Cox, GR, null Cox, null Merry, Hetrick, SE, Cox GR, Merry, SN, Sarah Hetrick, Hetrick SE, Merry SN   +8 more
core   +1 more source

Depression uncouples brain hate circuit [PDF]

, 2011
It is increasingly recognized that we need a better understanding of how mental disorders such as depression alter the brain's functional connections to improve both early diagnosis and therapy.
J Feng, Z Xue, Kendrick, Keith M., K M Kendrick, H Tao, T Ge, Liu, Zhening, Z Liu, S Guo, Feng, Jianfeng, Guo, Shuixia, Ge, Tian, Tao, H., Xue, Z.   +13 more
core   +1 more source

Metacognitive Therapy in Treatment-Resistant Psychosis:A Multiple-Baseline Study [PDF]

, 2013
Background: More effective psychological treatments for psychosis are required. Case series data and pilot trials suggest metacognitive therapy (MCT) is a promising treatment for anxiety and depression.
Wardle, Melissa, Morrison, Anthony P, Morrison, Anthony P., Morrison, A.P., Wells, A; id_orcid, Hutton, P., Hutton, Paul, Wardle, M., Wells, Adrian   +8 more
core   +1 more source

Benefits of group compassion-focused therapy for treatment-resistant depression: A pilot randomized controlled trial

, 2022
Major depression is one of the most common mental health problems worldwide. More than one-third of patients suffer from treatment-resistant depression (TRD).
Masuyama, A., Tsuchiya, Masao, Asano, Kenichi, Sensui, Toshihiko, Shiraishi, T., Paul Gilbert, Shiraishi, Tetsuya, Tetsuya Shiraishi, Sensui, T., Isato, A., Masao Tsuchiya, Shoji, Masami, Masuyama, Akihiro, Kenichi Asano, Yoko Okamoto, Okamoto, Y., Ohtani, T., Ayako Isato, Chris Irons, Toshihiko Sensui, Eiji Shimizu, Shimizu, Eiji, Gilbert, Paul, Irons, Chris, Asano, K., Isato, Ayako, Irons, C., Gilbert, P., Toshiyuki Ohtani, Shoji, M., Okamoto, Yoko, Tsuchiya, M., Shimizu, E., Masami Shoji, Ohtani, Toshiyuki, Akihiro Masuyama   +35 more
core   +1 more source

Case Report: Use of Subcutaneous Midazolam During an Episode of Catatonia

Frontiers in Psychiatry, 2021
Midazolam is a benzodiazepine (BZD) mainly used in anesthetic induction due to its pharmacokinetic features. Its place in the therapeutic management of catatonia remains to be determined. Here we present the case of a 65-year-old man who presented with a
Valentin Raymond, Etienne Véry, Adeline Jullien, Fréderic Eyvrard, Loic Anguill, Antoine Yrondi   +5 more
doaj   +1 more source

Psychoanalytic and psychodynamic therapies for depression. The evidence base. [PDF]

, 2008
David Taylor, a consultant psychotherapist at the Tavistock & Portman NHS Foundation Trust (120 Belsize Lane, London NW3 5BA, UK. Email: dtaylor@tavi-port.nhs.uk), is the clinical lead of the Tavistock Adult Depression Study (a randomised controlled ...
Taylor, David, David Taylor
core   +1 more source